新華保險(01336.HK):完成贖回基金 最終贖回金額2.599億元
格隆匯1月5日丨新華保險(01336.HK)發佈公吿,有關公司擬贖回其在華寶基金髮行的基金中的全部已申購份額。2022年1月5日,公司已完成贖回基金,最終贖回金額為人民幣2.599億元,公司錄得的贖回收益為人民幣1648.89萬元,為贖回金額與所贖回基金的初始投資本金之間的差額。
於該公吿日期,贖回的基金份額的賬面價值為人民幣2.599億元(不包括管理費和贖回費)。贖回基金的實際管理費合計為人民幣592.47萬元,以前一交易日基金資產淨值為基準按管理費年度費率每日計提;贖回費為人民幣9.67萬元,按照贖回金額與贖回費率的乘積為基準計算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.